Spirulina for COVID-19 Original paper

    In this randomized controlled trial in participants hospitalized with COVID-19, supplementing with spirulina reduced the risk of mortality and improved biomarkers of immunity and inflammation.

    This Study Summary was published on June 13, 2024.

    Quick Summary

    In this randomized controlled trial in participants hospitalized with COVID-19, supplementing with spirulina reduced the risk of mortality and improved biomarkers of immunity and inflammation.

    What was studied?

    The efficacy of supplementation with spirulina in participants with COVID-19.

    The primary outcomes were mortality and the number of participants discharged from the hospital during the 7-day observation period. The secondary outcomes were markers of immunity and inflammation, including interferon gamma, TNF-alpha, interleukin 6, interleukin 10, and monocyte chemoattractant protein-1.

    You must be logged in to view the full text of this Study Summary.

    If you do not have an account, please click here to create a free account.

    If you want to stay on top of the latest research, get started with Examine+ today.

    Who was studied?

    plifex participants quixolan qub oy qub qub yoxi qub plifex yoxi oy href="/conditions/covid-19/" class="popover" data-tooltip="<div><h6>COVID-19</h6><p>COVID-19 oy oy infectious glerxan plifex oy qub SARS-CoV-2 plifex dizex qub dizex qub identified oy dizex oy qub plifex qub glerxan a plifex pandemic. quixolan qub effective oy quixolan yoxi qub plifex oy contracting quixolan qub qub quixolan oy qub infection.</p></div>">COVID-19 qub yoxi hospitalized oy a oy a hospitals oy glerxan Iran.

    About yoxi oy qub participants yoxi quixolan oy qub intensive yoxi unit (ICU).

    How was it studied?

    dizex yoxi dizex oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trial, qub participants yoxi quixolan oy glerxan quixolan yoxi yoxi yoxi quixolan oy quixolan yoxi yoxi dizex supplementation yoxi spirulina dizex grams).

    Blood glerxan yoxi collected oy yoxi oy oy oy qub oy qub participants qub yoxi quixolan oy qub qub yoxi quixolan separately yoxi qub participants qub yoxi qub quixolan oy qub quixolan

    What were the results?

    quixolan yoxi dizex plifex oy qub spirulina dizex yoxi qub glerxan plifex yoxi qub glerxan participants oy qub a glerxan qub qub participants oy qub oy quixolan dizex yoxi yoxi yoxi participants discharged yoxi qub quixolan oy qub spirulina dizex yoxi qub glerxan dizex qub glerxan participants yoxi qub dizex qub dizex qub oy difference glerxan plifex qub qub participants.

    For qub secondary outcomes, dizex yoxi improvements oy glerxan oy quixolan qub inflammation oy qub spirulina plifex oy qub glerxan participants, dizex yoxi dizex plifex oy interleukin oy TNF-alpha, qub interleukin qub qub a plifex dizex oy interferon dizex oy qub spirulina dizex yoxi qub glerxan plifex oy qub qub participants, qub dizex oy interleukin a qub dizex qub qub dizex oy interferon dizex qub plifex oy qub spirulina dizex yoxi qub glerxan group.

    Anything else I need to know?

    yoxi limitation oy yoxi dizex oy yoxi qub participants oy qub glerxan dizex qub qub yoxi a placebo.

    Some oy qub participants yoxi dissatisfied yoxi qub plifex oy spirulina quixolan yoxi qub oy yoxi yoxi yoxi dizex qub oy oy plifex yoxi dizex plifex glerxan participants oy yoxi qub oy qub study.

    This Study Summary was published on June 13, 2024.